Medical genetics-based drug repurposing for Alzheimer's disease

Brain Res Bull. 2015 Jan:110:26-9. doi: 10.1016/j.brainresbull.2014.11.003. Epub 2014 Nov 22.

Abstract

Alzheimer's disease (AD) is a disease that threatens the elderly. No efficient therapeutic method is currently available to combat AD. Drug repurposing has provided a new route for AD drug discovery, and medical genetics has shown potential in target-based drug repurposing. We compared AD-associated genes with approved drug targets and found that three are targeted by 23 approved drugs. Thus, these drugs may be used to treat AD according to the medical genetic information of the targets. In vitro and in vivo experiments revealed that four drugs, all of which are angiotensin-converting enzyme (ACE) inhibitors, had potential to treat AD.

Keywords: Alzheimer's disease; Angiotensin-converting enzyme inhibitors; Drug repurposing; Medical genetics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / genetics*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Drug Repositioning / methods*
  • Humans
  • Nootropic Agents / pharmacology
  • Nootropic Agents / therapeutic use

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Nootropic Agents